Northwire Canada EditionThursday, October 15, 2026
Northwire
⌕
GOLD 4107.90 −1.7% SILVER 55.88 −6.1% COPPER 6.62 −1.6% OIL 95.09 +1.0% PALLADIUM 1096.50 −2.7% CIA 2.64 −0.4% BTO 7.09 −4.3% MCI 0.155 +0.0% CAN 0.065 +0.0% BLDS 0.335 +8.1% SAO 0.050 +0.0% SF 0.315 +0.0% BEA 0.055 −15.4% BMM 3.90 +11.1% AUGC 0.295 −13.2% MFG 3.34 −3.8% CDE 21.33 −7.7% CYG 0.160 −5.9% RSMX 0.100 −4.8% TUF 0.830 −5.7% GPG 0.285 −3.4% GOLD 4107.90 −1.7% SILVER 55.88 −6.1% COPPER 6.62 −1.6% OIL 95.09 +1.0% PALLADIUM 1096.50 −2.7% CIA 2.64 −0.4% BTO 7.09 −4.3% MCI 0.155 +0.0% CAN 0.065 +0.0% BLDS 0.335 +8.1% SAO 0.050 +0.0% SF 0.315 +0.0% BEA 0.055 −15.4% BMM 3.90 +11.1% AUGC 0.295 −13.2% MFG 3.34 −3.8% CDE 21.33 −7.7% CYG 0.160 −5.9% RSMX 0.100 −4.8% TUF 0.830 −5.7% GPG 0.285 −3.4%
Other Neutral

The Medicus Pension Plan reports 140% funded status and 13.7% investment return

Scotiabank’s earnings engine revs higher, but a physician‑plan headline leaves investors unimpressed.

Executive Summary
  • The latest item (June 3, 2026) reports that the Medicus Pension Plan achieved a 140% funded status, a 13.7% investment return in 2025, and 100% inflation protection for the fourth straight year.
  • The release mentions a physician‑focused registered pension plan with governing board composition, legislative efforts for expansion, and enhanced member benefits.
  • No reference to Scotiabank’s operations, financials, or strategy appears anywhere in the announcement. The connection to BNS is presumed to stem from a wealth‑management or administration role, but the release itself is entirely about Medicus.
Material Impact
  • There is no quantifiable impact on Scotiabank’s revenue, net income, capital ratios, or earnings per share.
  • The news does not alter the bank’s credit profile, liquidity position, growth outlook, or capital return trajectory.
  • In the context of the very strong Q2‑2026 results (net income +30% YoY, adjusted EPS of $2.02) and a series of accretive operating updates, this item is effectively background noise.
  • The market’s attention will remain on earnings momentum, credit‑cost normalization, and the MapleMark acquisition; this headline will not move the stock.
BNS · Price
Company Overview
  • Scotiabank is one of Canada’s Big Five banks, operating through Canadian Banking, International Banking (Pacific Alliance focus), Global Wealth Management, and Global Banking & Markets.
  • The strategy is centered on organic earnings growth, improving Canadian Banking ROE toward ~24% by 2028, scaling the U.S. presence (KeyCorp investment and MapleMark acquisition), and exiting non‑core Latin American markets (the Colombia/Costa Rica/Panama divestiture closed in late 2025).
  • The medium‑term target of 14%+ ROE is now expected by fiscal 2027, a year ahead of plan, per management’s Q1‑2026 call.
Read the original news release →

More from BANK OF NOVA SCOTIA (THE)